Clinical Trial

A Study to Evaluate the Real-world Experience and Satisfaction Associated With Ofatumumab

Completed
View on ClinicalTrials.gov →
Summary
The aim of this study was to assess physician and patient satisfaction with ofatumumab using data collected from physicians and their multiple sclerosis (MS) patients in real-world clinical practice across the United Kingdom (UK), France, Germany, Italy, Spain, China, Japan, and Brazil.
Protocol Amendment History 1 change
critical Trial completed 2026-06-16
Trial Details
NCT Number NCT07504783
Lead Sponsor Novartis Pharmaceuticals
Conditions Multiple Sclerosis
Enrollment 261 participants
Start Date 2026-01-22
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-15